TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02732899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT03904043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire
Description: -Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal biopsy samples
Description: -Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for ctDNA
Description: -Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after RT (if this visit aligns with a follow-up time point, one draw can be used to satisfy both time points), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)
Study: NCT00953927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A/AERAS-485
Description: Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Candida Skin Test Antigen
Description: 1 test, administered once as a placebo control.
Study: NCT04289584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and proprioception exercises
Description: Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
Study: NCT01374906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide LAR
Description: Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide LAR
Description: Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 LAR 30 mg
Description: starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 LAR 10 mg
Description: starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
Study: NCT00068653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg orally two times a day, taken with meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: ZD1839 250 mg po every day, taken with or without food.
Study: NCT01539291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet(s) administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet(s) administered orally twice daily
Study: NCT00057915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA peptide 1-6D
Description: CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
Study: NCT03994861

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Assessment of disability and behavior (by questionnaires)
Description: Assessment of disability and behavior (by questionnaires)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of disability and behavior (by questionnaires)
Description: Assessment of disability and behavior (by questionnaires)
Study: NCT04296617

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study: NCT00268528

Intervention type: BEHAVIORAL
Intervention: Compliance Monitoring
Description: Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Intervention: Methotrexate
Description: Given PO

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Description: Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
Study: NCT02709967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Material support
Description: Writing materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Material support
Description: Writing materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Material support
Description: Writing materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Economic
Description: Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Economic
Description: Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community dialogue
Description: Community dialogue (youth club meetings, community and parent meetings)
Study: NCT03468439

Intervention type: OTHER
Group type: OTHER
Intervention: Femoral nerve block with phenol
Study: NCT04681521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot and Cold compress, nursing interventions
Description: using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot and Cold compress, nursing interventions
Description: using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot and Cold compress, nursing interventions
Description: using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
Study: NCT04660981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal education
Description: Training Program on Fear of Childbirth Based on Motivational Interview Method
Study: NCT04201834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: capsule or tablet, 0.5 mg
Study: NCT02732899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYLEA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EYLEA
Study: NCT03942718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will obtain an individualized exercise program based on entrance examination on treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will obtain an individualized exercise program based on entrance examination on treadmill.
Study: NCT00844454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-pronged ethanol ablation
Description: Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
Study: NCT01953406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
Study: NCT05242679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique along with conventional physiotherapy exercises
Description: Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
Study: NCT04201834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioStamp nPoint device
Description: MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
Study: NCT05242679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy exercises
Description: Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
Study: NCT02290665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermosensitive gel rectal formulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermosensitive gel rectal formulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline enema

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline enema
Study: NCT00182689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT04474184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Receive vaginal kit for biospecimen collection
Study: NCT00639639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally
Study: NCT04474184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Attend focus group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03574129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Transition Package
Description: Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
Study: NCT01389908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
Study: NCT01806480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred proactive breastfeeding telephone support
Description: Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
Study: NCT02055352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 400 mcg twice a day via Breezhaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Fluticasone 250 mcg twice daily via Accuhaler® device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone 250 mcg twice daily via Accuhaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 mcg once daily via Breezhaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50 mcg twice daily via Diskus® device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg twice daily via Diskus® device
Study: NCT01858454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HALS
Description: In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
Study: NCT00639639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally
Study: NCT01858454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
Study: NCT00796718

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy
Description: Administered as prescribed according to normal clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine [Xeloda]
Description: 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
Study: NCT02133911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study: NCT01256398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV
Study: NCT00648232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage to care
Description: Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine referral to care
Description: Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine referral to care
Description: Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
Study: NCT01490177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food proteins
Description: Oral ingestion of Food proteins
Study: NCT01256398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood allogeneic HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood autologous HCT
Study: NCT04352010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Res-Up!
Description: Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMOTION
Description: REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wait-Control Group
Description: In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
Study: NCT02157311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four consecutive days on treatment and 3 days off
Description: All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
Study: NCT00384085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Subcutaneous injection up to 1 injection per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection once-a-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection once-a-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premixed Insulin
Description: Subcutaneous injection twice-a-day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Subcutaneous injection up to 3 injections per day.
Study: NCT02842775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance perturbation training
Description: perturbation training on the split-belt balance perturbance treadmill,
Study: NCT01256398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT00423436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking about 30-45 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking about 30-45 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response Telephone System
Description: IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR Plus Triage
Description: IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit.
Study: NCT00639639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study: NCT04533334

Intervention type: PROCEDURE
Intervention: FOB measurement
Description: A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
Study: NCT03391778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADP adoptive cell therapy
Description: No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT00787345

Intervention type: OTHER
Group type: OTHER
Intervention: simulation based training
Description: simulation based training in aseptic techniques that included specified AT categories
Study: NCT01256398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study: NCT02912533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-131
Study: NCT02032901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study: NCT02419157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etching with 36% phosphoric acid
Description: Etch: selective 36% phosphoric acid enamel etching

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etching with 36% phosphoric acid
Description: Etch: selective 36% phosphoric acid enamel etching

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No selective enamel etching with 36% phosphoric acid
Description: Non-etch: without phosphoric acid selective enamel etching

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No selective enamel etching with 36% phosphoric acid
Description: Non-etch: without phosphoric acid selective enamel etching

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil SE Bond

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil SE Bond

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeno V

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeno V